{
  "first_published_at": "2013-05-29", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON282739", 
  "title": "Thalidomide: risk of second primary malignancies", 
  "tags": "{\"parsed_therapeutic\": [\"cancer\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Cancer\"]}", 
  "_document_number": 74, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "cancer"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Thalidomide: risk of second primary malignancies</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: May 2013</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--Patients treated with thalidomide have an increased risk of haematological second primary malignancies (acute myeloid leukaemia and myelodysplastic syndromes). Healthcare professionals should consider this risk when deciding whether to treat patients with thalidomide, and should monitor for the occurrence of these conditions.-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>Patients treated with thalidomide have an increased risk of haematological second primary malignancies (acute myeloid leukaemia and myelodysplastic syndromes). Healthcare professionals should consider this risk when deciding whether to treat patients with thalidomide, and should monitor for the occurrence of these conditions<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Thalidomide (Thalidomide Celgene) is licensed for use in combination with melphalan and prednisone as first-line treatment for patients with untreated multiple myeloma who are age 65 years or older, or those who are ineligible for high-dose chemotherapy. Thalidomide is an immunomodulatory agent, which has antineoplastic, antiangiogenic, and proerythropoietic properties.</p>\n\n<p>In November 2011, we published information about the <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON134927\" target=\"_blank\">risk of development of second primary malignancies with lenalidomide</a> (a structural analogue of thalidomide) in patients treated for myeloma. The risk of second primary malignancies associated with thalidomide was investigated because of the similarities between thalidomide and lenalidomide.</p>\n\n<p>The data show an increased risk of haematological second primary malignancies (acute myeloid leukaemia and myelodysplastic syndromes) in an ongoing study of patients with newly diagnosed multiple myeloma who were receiving melphalan, prednisone, and thalidomide, compared with patients treated with lenalidomide plus dexamethasone. The risk of acute myeloid leukaemia or myelodysplastic syndromes with thalidomide increased from approximately 2% after 2 years to 4% after 3 years.</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<ul>\n<li>Before starting thalidomide treatment in combination with melphalan and prednisone, take into account both the likely benefit expected from thalidomide and the risk of acute myeloid leukaemia and myelodysplastic syndromes</li>\n\n<li>Carefully evaluate patients before and during treatment using standard cancer screening and provide appropriate treatment</li>\n</ul>\n</div>\n\n<p><strong>Further information</strong></p>\n\n<p><a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON270715\" target=\"_blank\">Letter sent to healthcare professionals, April 2013</a></p>\n\n<p>BNF section 8.2.4 <a href=\"http://www.bnf.org/bnf/search.htm?q=thalidomide\" target=\"_blank\">Other immunomodulating drugs</a></p>\n\n<p>&#160;</p>\n\n<p><em>Article citation: Drug Safety Update May 2013 vol 6, issue 10: A2.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Thalidomide (Thalidomide Celgene) is licensed for use in combination with melphalan and prednisone as first-line treatment for patients with untreated multiple myeloma who are age 65 years or older, or those who are ineligible for high-dose chemotherapy. Thalidomide is an immunomodulatory agent, which has antineoplastic, antiangiogenic, and proerythropoietic properties.</p>\n\n<p>In November 2011, we published information about the <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON134927\" target=\"_blank\">risk of development of second primary malignancies with lenalidomide</a> (a structural analogue of thalidomide) in patients treated for myeloma. The risk of second primary malignancies associated with thalidomide was investigated because of the similarities between thalidomide and lenalidomide.</p>\n\n<p>The data show an increased risk of haematological second primary malignancies (acute myeloid leukaemia and myelodysplastic syndromes) in an ongoing study of patients with newly diagnosed multiple myeloma who were receiving melphalan, prednisone, and thalidomide, compared with patients treated with lenalidomide plus dexamethasone. The risk of acute myeloid leukaemia or myelodysplastic syndromes with thalidomide increased from approximately 2% after 2 years to 4% after 3 years.</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<ul>\n<li>Before starting thalidomide treatment in combination with melphalan and prednisone, take into account both the likely benefit expected from thalidomide and the risk of acute myeloid leukaemia and myelodysplastic syndromes</li>\n\n<li>Carefully evaluate patients before and during treatment using standard cancer screening and provide appropriate treatment</li>\n</ul>\n</div>\n\n<p><strong>Further information</strong></p>\n\n<p><a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON270715\" target=\"_blank\">Letter sent to healthcare professionals, April 2013</a></p>\n\n<p>BNF section 8.2.4 <a href=\"http://www.bnf.org/bnf/search.htm?q=thalidomide\" target=\"_blank\">Other immunomodulating drugs</a></p>\n\n<p>&#160;</p>\n\n<p><em>Article citation: Drug Safety Update May 2013 vol 6, issue 10: A2.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2013-05-01", 
  "date_last_modified": "2013-09-10", 
  "_assets": [], 
  "_item_id": 74, 
  "summary": "Patients treated with thalidomide have an increased risk of haematological second primary malignancies (acute myeloid leukaemia and myelodysplastic syndromes). Healthcare professionals should consider this risk when deciding whether to treat patients with thalidomide, and should monitor for the occurrence of these conditions", 
  "body": "Article date: May 2013\n\nThalidomide (Thalidomide Celgene) is licensed for use in combination with melphalan and prednisone as first-line treatment for patients with untreated multiple myeloma who are age 65 years or older, or those who are ineligible for high-dose chemotherapy. Thalidomide is an immunomodulatory agent, which has antineoplastic, antiangiogenic, and proerythropoietic properties.\n\nIn November 2011, we published information about the [risk of development of second primary malignancies with lenalidomide](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON134927) (a structural analogue of thalidomide) in patients treated for myeloma. The risk of second primary malignancies associated with thalidomide was investigated because of the similarities between thalidomide and lenalidomide.\n\nThe data show an increased risk of haematological second primary malignancies (acute myeloid leukaemia and myelodysplastic syndromes) in an ongoing study of patients with newly diagnosed multiple myeloma who were receiving melphalan, prednisone, and thalidomide, compared with patients treated with lenalidomide plus dexamethasone. The risk of acute myeloid leukaemia or myelodysplastic syndromes with thalidomide increased from approximately 2% after 2 years to 4% after 3 years.\n\nAdvice for healthcare professionals:  \n  \n  * Before starting thalidomide treatment in combination with melphalan and prednisone, take into account both the likely benefit expected from thalidomide and the risk of acute myeloid leukaemia and myelodysplastic syndromes  \n  * Carefully evaluate patients before and during treatment using standard cancer screening and provide appropriate treatment  \n  \nFurther information\n\n[Letter sent to healthcare professionals, April 2013](http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON270715)\n\nBNF section 8.2.4 [Other immunomodulating drugs](http://www.bnf.org/bnf/search.htm?q=thalidomide)\n\n \n\nArticle citation: Drug Safety Update May 2013 vol 6, issue 10: A2.\n"
}